Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. price
About Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
- Stock ticker
- KPTI
- Company
- Karyopharm Therapeutics Inc.
- Industry
- Healthcare
- Category
- US
- Stock split / reverse split
- 151
- Launch date
- Nov 6, 2013
- Listed exchange
- NASDAQ
Financials
Summary: KPTI reported Revenue of 33.43M (-11.86%), beating expectations; EPS of -2.32 (+46.30%), missing expectations.
Dividends
Karyopharm Therapeutics Inc. conversion tables
 |  |
|---|---|
| 0.5 KPTI | 0.21445 USD |
| 1 KPTI | 0.4289 USD |
| 5 KPTI | 2.144 USD |
| 10 KPTI | 4.289 USD |
| |
|---|---|
| 0.5 USD | 1.165 KPTI |
| 1 USD | 2.331 KPTI |
| 5 USD | 11.65 KPTI |
| 10 USD | 23.31 KPTI |
More to explore
FAQ
KPTI is trading at $0.43, +19.60% over the last 24 hours. Track live moves on the price chart at the top of this page.
The KPTI stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. KPTI is currently trading at $0.43, +19.60% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on KPTI price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the Healthcare sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. KPTI's P/E ratio is currently -- — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from KPTI; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against KPTI's historical range and other companies in the Healthcare sector.
Karyopharm Therapeutics Inc.'s market cap is currently 9.39M USD. Market cap is calculated as stock price × total shares outstanding.
Disclaimer
The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.
OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.